CompletedNCT00046384
Aripiprazole for acute symptoms in bipolar I
About this title
Read the official source — NCT00046384Medication studyAges 18+United States + ArgentinaBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Scottsdale and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Argentina
- Age range
- Over 18 Years
- Official registry ID
- NCT00046384
- Official title
Show the full official title
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Scottsdale, United States · Little Rock, United States · Chula Vista, United States
11 more locations
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Washington D.C., United States
- Winter Park, United States
- Staten Island, United States
- Oklahoma City, United States
- Nashville, United States
- Falls Church, United States
- Bellevue, United States
- Mendoza, Argentina
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
